TY - JOUR
T1 - Five‐year survival of patients with disseminated nonseminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin
AU - Stoter, Gerrit
AU - Vendrik, Cornelis P J
AU - Struyvenberg, Albert
AU - Sleyfer, Dirk Th
AU - Vriesendorp, Rob
AU - Koops, Heimen Schraffordt
AU - van Oosterom, Allan T.
AU - Ten Huinink, Wim W Bokkel
AU - Pinedo, Herbert M.
PY - 1984
Y1 - 1984
N2 - Ninety‐one patients with disseminated testicular non‐seminomas were treated with 3 to 4 cycles of cisplatin, vinblastine, and bleomycin (PVB) induction chemotherapy followed by cisplatin and vinblastine maintenance therapy for 1 year. The follow‐up of these patients ranges from 24 to 66 months. Forty‐nine (54%) patients achieved complete remission by chemotherapy alone and 14 (15%) were rendered free of tumor by surgery after chemotherapy, for a total complete remission rate of 69%. Three complete responders relapsed within 13 months, and two died. One additional complete responder died of a non‐cancer‐related cause. One of the surgical complete responders relapsed and died. Overall, 58 (64%) patients remain free of disease. The 5‐year survival is 95% for complete responders, 32% for partial responders, and 72% overall. This combination regimen has significantly improved the survival of disseminated testicular cancer patients, equaling that of Stage II patients in older literature.
AB - Ninety‐one patients with disseminated testicular non‐seminomas were treated with 3 to 4 cycles of cisplatin, vinblastine, and bleomycin (PVB) induction chemotherapy followed by cisplatin and vinblastine maintenance therapy for 1 year. The follow‐up of these patients ranges from 24 to 66 months. Forty‐nine (54%) patients achieved complete remission by chemotherapy alone and 14 (15%) were rendered free of tumor by surgery after chemotherapy, for a total complete remission rate of 69%. Three complete responders relapsed within 13 months, and two died. One additional complete responder died of a non‐cancer‐related cause. One of the surgical complete responders relapsed and died. Overall, 58 (64%) patients remain free of disease. The 5‐year survival is 95% for complete responders, 32% for partial responders, and 72% overall. This combination regimen has significantly improved the survival of disseminated testicular cancer patients, equaling that of Stage II patients in older literature.
UR - http://www.scopus.com/inward/record.url?scp=0021149355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021149355&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19841015)54:8<1521::AID-CNCR2820540808>3.0.CO;2-8
DO - 10.1002/1097-0142(19841015)54:8<1521::AID-CNCR2820540808>3.0.CO;2-8
M3 - Article
C2 - 6206937
AN - SCOPUS:0021149355
SN - 0008-543X
VL - 54
SP - 1521
EP - 1524
JO - Cancer
JF - Cancer
IS - 8
ER -